FDA Official Who Oversaw Aducanumab Approval Retiring
An FDA official who oversaw the approval of the controversial Alzheimer's therapy aducanumab is retiring from the agency to 'explore other opportunities.'
Stay updated with breaking news from Billy Dunn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An FDA official who oversaw the approval of the controversial Alzheimer's therapy aducanumab is retiring from the agency to 'explore other opportunities.'
The recent controversy on the Alzheimer's drug approvals already had an executive stepping down.
(Reuters) - The U.S. Food and Drug Administration neurosciences head Billy Dunn will retire from his role effective immediately, the health regulator ...
By Mariam ESunny and Raghav Mahobe (Reuters) -The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc's drug for the treat...
Reata Pharmaceuticals is aiming to make the drug omaveloxolone available by the second quarter of 2023